This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Pharma has long taken small steps toward phasing out animal ...

The last few weeks have been busy for Jim Corbett. Corbett, the CEO of organ-chip developer Emulate, has been fielding requests from potential clients, as well as from early investors who say they ...

(Reuters) -Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near ...

For decades, preclinical testing in mice, rats, and nonhuman primates has been a crucial part of drug development, an important although not infallible way to ensure some measure of safety for human ...

The US Food and Drug Administration (FDA) has taken another step away from animal testing – this time through draft guidance encouraging the reduction or cessation of non-human primate toxicity ...

Carlin is a vice president at Pathway Policy Group and a veterinarian. Paragas is the CEO and founder of DVLP Medicines and a virologist. The Food and Drug Administration’s recent decision to phase ...

Technical.ly is a free news resource thanks to financial supporters like Certara, a Technical.ly client, which sponsored this article. It was reviewed before publication. Learn more about Certara.

Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy ...

The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain monoclonal antibodies (mAbs), the latest expansion of the regulator’s efforts to eliminate animal ...

The push to abandon animal testing is gaining momentum, driven by the realization that it is costly, unreliable and ...